The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10087 malaria professionals are enjoying the free benefits of MalariaWorld today

dihydroartemisinin-piperaquine

Plasmodium falciparum dihydroartemisinin-piperaquine failures in Cambodia are associated with mutant K13 parasites presenting high survival rates in novel piperaquine in vitro assays: retrospective and prospective investigations

January 5, 2016 - 15:13 -- Open Access
Author(s): 
Duru V, Khim N, Menard D, et al.
Reference: 
BMC Medicine 2015, 13 :305 (22 December 2015)

The prospective study assessed ex vivo PSA survival rate alongside K13 polymorphism of isolates collected from patients enrolled in an open-label study with dihydroartemisinin-piperaquine for uncomplicated P. falciparum malaria in Cambodia (registered ACTRN12615000696594).

Country: 

Maximizing antimalarial efficacy and the importance of dosing strategies

May 12, 2015 - 15:57 -- Open Access
Author(s): 
James G Beeson, Philippe Boeuf and Freya JI Fowkes
Reference: 
BMC Medicine 2015, 13:110

In the most recent study, an analysis of clinical trials of artesunate-amodiaquine, widely used among children in Africa, revealed a superior efficacy for fixed-dose combination tablets compared to loose non-fixed dose combinations.

In vivo monitoring of dihydroartemisinin-piperaquine sensitivity in Plasmodium falciparum along the China-Myanmar border of Yunnan Province, China from 2007 to 2013

February 26, 2015 - 14:49 -- Open Access
Author(s): 
Hui Liu, Heng-lin Yang, Jian-wei Xu, et al.
Reference: 
Malaria Journal 2015, 14:47 (5 February 2015)

 Polymerase chain reaction (PCR) was conducted to distinguish between re-infection and recrudescence, to confirm the Plasmodium species. The data were entered and analysed by the Kaplan-Meier method. Treatment outcome was assessed according to the WHO recommended standards.

The diminishing returns of atovaquone-proguanil for elimination of Plasmodium falciparum malaria: modelling mass drug administration and treatment

September 30, 2014 - 19:40 -- Open Access
Author(s): 
Maude RJ, Nguon C, Dondorp AM, White LJ, White NJ
Reference: 
Malaria Journal 2014, 13 :380 (24 September 2014)

A deterministic, population level, mathematical model was developed based on data from Cambodia to explore the possible effects of large-scale use of A-P compared to dihydroartemisinin-piperaquine ACT for mass drug administration and/or treatment of P. falciparum malaria, with and without adjunctive primaquine (PQ) and long-lasting insecticide-treated bed nets (LLIN). The aim was local elimination.

Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling

April 16, 2014 - 19:05 -- Open Access
Author(s): 
Hodel EM, Kay K, Hayes DJ, Terlouw DJ, Hastings IM
Reference: 
Malaria Journal 2014, 13 :138 (7 April 2014)

The model highlights the sub-optimally low ratio of DHA:PPQ which, in combination with the narrow therapeutic dose range of PPQ compared to DHA that drives the weight or age cut-offs, leaves DHA at a high risk of under-dosing.

Blackwater fever in an uncomplicated Plasmodium falciparum patient treated with dihydroartemisinin-piperaquine

April 2, 2014 - 19:44 -- Open Access
Author(s): 
Lon C, Spring M, Sok S, Chann S, Bun R, Ittiverakul M, Buathong N, Thay K, Kong N, You Y, Kuntawunginn W, Lanteri CA, Saunders DL
Reference: 
Malaria Journal 2014, 13 :96 (14 March 2014)

Here is an unusual case of BWF, which developed on day 2 of treatment for uncomplicated Plasmodium falciparum infection with dihydroartemisinin-piperaquine (DHA-PIP) with documented evidence of concomitant seropositivity for Chikungunya infection.

The Effect of Dosing Regimens on the Antimalarial Efficacy of Dihydroartemisinin-Piperaquine: A Pooled Analysis of Individual Patient Data

December 10, 2013 - 07:08 -- Open Access
Author(s): 
The WorldWide Antimalarial Resistance Network (WWARN) DP. Study Group
Reference: 
PLoS Med 10(12): e100156

Background

Dihydroartemisinin-piperaquine (DP) is increasingly recommended for antimalarial treatment in many endemic countries; however, concerns have been raised over its potential under dosing in young children. We investigated the influence of different dosing schedules on DP's clinical efficacy.

Medical Treatment: 

A randomized trial of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated malaria among children in western Kenya

July 23, 2013 - 16:44 -- Open Access
Author(s): 
Agarwal A, McMorrow M, Onyango P, Otieno K, Odero C, Williamson J, Kariuki S, Kachur SP, Slutsker L, Desai M
Reference: 
Malaria Journal 2013, 12:254 (19 July 2013)
MalariaWorld

The efficacy of AL and dihydroartemisinin-piperaquine (DP) were evaluated for the treatment of uncomplicated malaria in children aged six to 59 months in western Kenya.

Country: 
Subscribe to RSS - dihydroartemisinin-piperaquine